8-K: MBX Canvuparatide Phase 2 Hits Primary Endpoint

MBX Biosciences announced positive topline results from its Phase 2 Avail clinical trial for once-weekly canvuparatide in chronic hypoparathyroidism, achieving its primary endpoint.

Summary

• Canvuparatide achieved the primary composite endpoint in the Phase 2 Avail trial with a 63% responder rate (30/48 patients) at 12 weeks, compared to 31% for placebo (5/16 patients) (p=0.042).
• The responder rate further increased to 79% at 6 months in the Open-Label Extension (OLE) among 44 out of 56 evaluable patients.
• All 64 patients completed the 12-week study, and 94% (60 patients) elected to enroll in the two-year OLE.
• Pharmacokinetic findings were consistent with Phase 1 results, supporting a once-weekly dosing schedule.
• Bone turnover and formation markers (BSAP, CTx, P1NP) increased over 12 weeks compared to placebo, indicating enhanced bone remodeling.
• In patients with elevated urine calcium at screening, mean urine calcium was reduced by 48% in canvuparatide-treated patients compared with 33% on placebo at Week 12.
• Canvuparatide was generally well-tolerated across all doses, with no discontinuations related to the treatment and no serious adverse events reported.
• Most treatment-emergent adverse events were categorized as mild or moderate.
• Injection site reactions occurred in 19% of the pooled treatment group versus 13% in the placebo group.
• No deaths were reported during the trial.

Sentiment

Score: 9

Explanation: The trial results are overwhelmingly positive, meeting the primary endpoint with statistical significance and showing improved efficacy and a good safety profile in the open-label extension. The once-weekly dosing is a significant advantage, positioning the drug as a potential best-in-class treatment.

Positives

• Achieved the primary composite endpoint with statistical significance (p=0.042) at 12 weeks, demonstrating a 63% responder rate for canvuparatide versus 31% for placebo.
• Sustained and improved responder rate of 79% at 6 months in the Open-Label Extension, indicating long-term efficacy.
• High patient retention with 100% completion of the 12-week study and 94% enrollment in the OLE, suggesting patient satisfaction and tolerability.
• Favorable safety profile, with canvuparatide being generally well-tolerated, no treatment-related serious adverse events, and no discontinuations due to the drug.
• Positive impact on bone activity, with increased bone turnover and formation markers.
• Demonstrated a meaningful reduction in urine calcium in patients with elevated baseline levels, addressing a key complication of hypoparathyroidism.
• Pharmacokinetic data supports a convenient once-weekly dosing schedule, a significant advantage for patient adherence and quality of life.

Negatives

• Injection site reactions were slightly more frequent in the pooled treatment group (19%) compared to placebo (13%).
• Some treatment-emergent adverse events, such as headache, hypercalcemia, arthralgia, and nausea, were observed, though mostly mild or moderate.

Risks

• Risks relating to the Company's research and development activities.
• MBX Biosciences' ability to execute on its strategy, including obtaining requisite regulatory approvals on the expected timeline, if at all.
• Uncertainties relating to preclinical and clinical development activities.
• The Company's dependence on third parties to conduct clinical trials, manufacture its product candidates, and develop and commercialize its product candidates, if approved.
• MBX Biosciences' ability to attract, integrate, and retain key personnel.
• Risks related to the Company's financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved.
• Risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities.
• Risks related to establishing and maintaining MBX Biosciences' intellectual property protections.
• Risks related to the competitive landscape for MBX Biosciences' product candidates.
• Actual results could differ materially from forward-looking statements due to various factors.

Future Outlook

MBX Biosciences plans to initiate a Phase 3 clinical trial for once-weekly canvuparatide in 2026. The company will present additional Phase 2 data at an upcoming medical meeting in October 2025, request an End-of-Phase 2 meeting with the FDA, share full Phase 2 results in a publication, and report 52-week OLE follow-up data in 2026.

Management Comments

• "The results from the Avail trial are encouraging. A once-weekly therapy could simplify administration and help address important unmet medical needs of patients with hypoparathyroidism." Mishaela Rubin, MD, MS, Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons and an investigator in the Avail clinical trial.
• "We are very pleased with the clinically meaningful and statistically significant topline results from our once-weekly canvuparatide Phase 2 trial. These data reinforce our conviction that canvuparatide could become a potential best-in-class treatment for hypoparathyroidism and demonstrate the value of our novel Precision Endocrine Peptide platform technology." Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences.
• "We believe the totality of the data support a once-weekly product profile with continuous infusion-like PTH exposure. These 12-week and 6-month results represent the potential for a meaningful improvement over current treatment options for HP patients and provide a strong foundation for further development." Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences.
• "We are thrilled with these trial results. For so many in our community, life with hypoparathyroidism means living with constant symptoms and the limitations of daily supplements. A once-weekly treatment option that maintains stable calcium control while reducing the day-to-day burden would be a major step forward." Patty Keating, Executive Director of the HypoPARAthyroidism Association.

Industry Context

Hypoparathyroidism is a rare endocrine disease affecting over 250,000 individuals in the U.S. and E.U., representing a significant unmet medical need. Current standard of care, primarily high doses of oral calcium and active vitamin D supplements, does not address the underlying parathyroid hormone (PTH) deficiency and can lead to complications. Existing daily PTH replacement therapies, such as Palopegteriparatide and Eneboparatide (in Phase 3), offer improvements but still require frequent administration. Canvuparatide, designed as a once-weekly PTH replacement therapy, aims to provide continuous, infusion-like PTH exposure, potentially offering a more convenient and effective treatment option that could simplify patient regimens and reduce complications compared to current daily therapies and standard care.

Comparison to Industry Standards

• Canvuparatide's 63% responder rate at Week 12 and 79% at 6 months in the OLE compares favorably to other injectable PTH therapies.
• One 'Once-Daily Injectable Phase 2 Responder Rates' showed 71% at Week 4 and 27% at Week 26, notably failing to achieve its primary endpoint with statistical significance at Week 4.
• An 'Once-Daily Injectable FDA-Approved Label Responder Rates' showed a 50% responder rate at Week 26.
• Canvuparatide's once-weekly dosing (52 injections/year) offers a significant convenience advantage over daily injectable therapies (365 injections/year), potentially improving patient adherence and quality of life.

Stakeholder Impact

• Shareholders: The positive clinical trial results are highly likely to increase investor confidence and potentially the company's share price, indicating strong progress in its pipeline.
• Patients with Hypoparathyroidism: The development of a once-weekly treatment option could significantly improve their quality of life by simplifying treatment regimens, reducing pill burden, and providing more stable calcium control.
• Healthcare Providers: A new, potentially best-in-class, and more convenient treatment option for managing chronic hypoparathyroidism could enhance patient care and outcomes.
• Employees: Positive clinical milestones can boost morale and provide job security, attracting top talent.

Next Steps

• Present Phase 2 topline results at the International HypoPARAthyroidism Conference (Oct 2025).
• Request End-of-Phase 2 meeting with the FDA.
• Share full Phase 2 results at a major medical meeting and in a publication.
• Report 52-week OLE follow-up data in 2026.
• Plan to initiate a global Phase 3 clinical trial in 2026.

Key Dates

Recommendation

The Phase 2 results for canvuparatide are exceptionally strong, demonstrating statistically significant efficacy and a favorable safety profile, with a compelling once-weekly dosing advantage over existing and developing therapies. The high responder rates at both 12 weeks and 6 months, coupled with positive biomarker data and high patient retention in the OLE, significantly de-risk the program. The planned progression to Phase 3 in 2026 positions the company for a potential best-in-class product in a market with significant unmet needs. This represents a strong catalyst for future growth and shareholder value, making it a compelling investment opportunity.

Keywords

Hypoparathyroidism, Canvuparatide, MBX Biosciences, Phase 2 Clinical Trial, Endocrine Disorders, Peptide Therapy, Orphan Drug, PTH Replacement Therapy, Biopharmaceutical, Clinical-stage